Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
Debt to Equity
0
ROE
-0.82 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.72
CFO
$-68.29 Mln
EBITDA
$-79.02 Mln
Net Profit
$-93.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NanoViricides (NNVC)
| -8.64 | 0.50 | 9.79 | 16.65 | -8.04 | -28.62 | -29.05 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
NanoViricides (NNVC)
| 39.81 | -8.11 | -70.16 | 29.62 | 14.34 | -37.25 | -77.09 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza... indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. Address: 1 Controls Drive, Shelton, CT, United States, 06484 Read more
Executive Chairman, President, CEO & Secretary
Dr. Anil R. Diwan Ph.D.
Executive Chairman, President, CEO & Secretary
Dr. Anil R. Diwan Ph.D.
Headquarters
Shelton, CT
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NanoViricides Inc (NNVC) stood at $ 13 Mln as on 31-Dec-24
The share price of NanoViricides Inc (NNVC) is $1.31 (NYSE) as of 23-Apr-2025 14:30 EDT. NanoViricides Inc (NNVC) has given a return of -8.04% in the last 3 years.
NanoViricides Inc (NNVC) has a market capitalisation of $ 21 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of NanoViricides Inc (NNVC) is 2.00 times as on 22-Apr-2025, a 9% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of NanoViricides Inc (NNVC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NanoViricides Inc (NNVC) and enter the required number of quantities and click on buy to purchase the shares of NanoViricides Inc (NNVC).
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. Address: 1 Controls Drive, Shelton, CT, United States, 06484
The CEO & director of Dr. Anil R. Diwan Ph.D.. is NanoViricides Inc (NNVC), and CFO & Sr. VP is Dr. Anil R. Diwan Ph.D..
There is no promoter pledging in NanoViricides Inc (NNVC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| NanoViricides Inc. (NNVC) | Ratios |
|---|---|
|
Return on equity(%)
|
-85.72
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NanoViricides Inc (NNVC) was $0 Mln.
$-0.03
(
